Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. HON
4. KBH
5. MRK
6. HTZ
7. INFY
8. HONA
9. TTWO
10. QCOM

Go back to Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age

Mizuho Securities Reiterates Buy Rating on Pfizer (PFE) After Speaking with Management

May 18, 2020 7:01 AM EDT

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $42.00 price target on Pfizer (NYSE: PFE) following a conference call with management. Pfizer released updated data on their Duchenne Muscular Dystrophy (DMD) candidate at ASGCT.

Divan's overall conclusion is unchanged in that the... More